The former global head of pharma intellectual property at Novartis has told IAM that life sciences companies should consider a more tech-like approach to IP management, involving licensing out development patents to competitors, rather than seeking to maintain market exclusivity on all incremental innovations. As well as making increasing commercial sense, such a strategy, he suggested, could help the pharmaceuticals industry to avoid negative perceptions and forestall a political backlash against life sciences patents.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

Excellent articles and focus on best practices.

Ruud Peters
Philips Intellectual Property & Standards


Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?